Nicholas Maestas - 17 Jul 2026 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: Chief Financial Officer
Issuer ticker: RANI
Reported as of: 17 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jul 2026, 16:51:09 UTC
Prior SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Carlos Perez, Attorney-in-Fact

Key filing fact

Nicholas Maestas filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 21 Jul 2026.

Key facts

This page summarizes Nicholas Maestas's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jul 2026, 16:51.

Change

Previous filing in this sequence was filed on 08 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001871423 Primary reporting owner

Maestas Nicholas

Relationship: Chief Financial Officer
Address: C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE, SAN JOSE
Signature: /s/ Carlos Perez, Attorney-in-Fact
Signature date: 21 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RANI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +2,000,000
Change %
Price: $0.000000^*
Shares after: 2,000,000
Date: 17 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 2,000,000
Exercise price: $0.6973
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 29, 2027; and 1/48th of the shares subject to the option vest monthly thereafter over the remaining three years, subject to the Reporting Person's Continuous Service (as defined in the Company's 2026 Inducement Plan) through each such vesting date.